{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:48:59Z","timestamp":1774352939248,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biomedical Informatics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jbi.2023.104420","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T22:53:13Z","timestamp":1686869593000},"page":"104420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-1709","authenticated-orcid":false,"given":"Yizhe","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Bechler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigam","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbi.2023.104420_b1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.0887-378X.2004.00327.x","article-title":"Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages","volume":"82","author":"Kravitz","year":"2004","journal-title":"Milbank Q."},{"key":"10.1016\/j.jbi.2023.104420_b2","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine \u2014 Reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbi.2023.104420_b3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The predictive approaches to treatment effect heterogeneity (PATH) statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbi.2023.104420_b4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1214\/12-AOAS593","article-title":"Estimating treatment effect heterogeneity in randomized program evaluation","volume":"7","author":"Imai","year":"2013","journal-title":"Ann. Appl. Stat."},{"key":"10.1016\/j.jbi.2023.104420_b5","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1073\/pnas.1804597116","article-title":"Meta-learners for estimating heterogeneous treatment effects using machine learning","volume":"116","author":"K\u00fcnzel","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jbi.2023.104420_b6","series-title":"Handbook of Matching and Weighting Adjustments for Causal Inference","article-title":"Treatment heterogeneity with survival outcomes","author":"Xu","year":"2023"},{"key":"10.1016\/j.jbi.2023.104420_b7","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1073\/pnas.1510489113","article-title":"Recursive partitioning for heterogeneous causal effects: Table 1","volume":"113","author":"Athey","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jbi.2023.104420_b8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/biomet\/asaa076","article-title":"Quasi-oracle estimation of heterogeneous treatment effects","volume":"108","author":"Nie","year":"2020","journal-title":"Biometrika"},{"key":"10.1016\/j.jbi.2023.104420_b9","series-title":"survlearners: Metalearners for survival data. R package version 0.0.1","author":"Xu","year":"2022"},{"key":"10.1016\/j.jbi.2023.104420_b10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: Epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.jbi.2023.104420_b11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.118.035012","article-title":"Early risks of death, stroke\/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry","volume":"139","author":"Bassand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jbi.2023.104420_b12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jbi.2023.104420_b13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials","volume":"154","author":"Investigators","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jbi.2023.104420_b14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jbi.2023.104420_b15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jbi.2023.104420_b16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1160\/TH11-02-0089","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective","volume":"105","author":"Sorensen","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jbi.2023.104420_b17","first-page":"1968","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.jbi.2023.104420_b18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.cjca.2015.09.012","article-title":"Uninterrupted new oral anticoagulants compared with uninterrupted vitamin K antagonists in ablation of atrial fibrillation: A meta-analysis","volume":"32","author":"Nairooz","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jbi.2023.104420_b19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor\u2019s choice-efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.jbi.2023.104420_b20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jbi.2023.104420_b21","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jbi.2023.104420_b22","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: Systematic review and meta-analysis","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jbi.2023.104420_b23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-017-0156-y","article-title":"NOACs replace VKA as preferred oral anticoagulant among new patients: A drug utilization study in 560 pharmacies in The Netherlands","volume":"16","author":"Van den Heuvel","year":"2018","journal-title":"Thromb. J."},{"key":"10.1016\/j.jbi.2023.104420_b24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbi.2023.104420_b25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1160\/TH15-06-0497","article-title":"Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation","volume":"114","author":"Seeger","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jbi.2023.104420_b26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbi.2023.104420_b27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jbi.2023.104420_b28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256338","article-title":"Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"16","author":"Reinhardt","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jbi.2023.104420_b29","series-title":"Evaluating treatment prioritization rules via rank-weighted average treatment effects","author":"Yadlowsky","year":"2021"},{"key":"10.1016\/j.jbi.2023.104420_b30","series-title":"International Conference on Artificial Intelligence and Statistics","first-page":"9280","article-title":"Calibration error for heterogeneous treatment effects","author":"Xu","year":"2022"},{"key":"10.1016\/j.jbi.2023.104420_b31","series-title":"Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate","author":"Ingelheim","year":"2019"},{"key":"10.1016\/j.jbi.2023.104420_b32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jbi.2023.104420_b33","first-page":"103","article-title":"Bonferroni and \u0160id\u00e1k corrections for multiple comparisons","volume":"3","author":"Abdi","year":"2007","journal-title":"Encycl. Meas. Stat."},{"key":"10.1016\/j.jbi.2023.104420_b34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jbi.2023.104420_b35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.jbi.2023.104420_b36","series-title":"Identifying Informative Biological Markers in High-Dimensional Genomic Data and Clinical Trials","author":"Signorovitch","year":"2007"},{"key":"10.1016\/j.jbi.2023.104420_b37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/bimj.200900028","article-title":"L1 penalized estimation in the Cox proportional hazards model","volume":"52","author":"Goeman","year":"2010","journal-title":"Biom. J."},{"key":"10.1016\/j.jbi.2023.104420_b38","doi-asserted-by":"crossref","DOI":"10.1080\/01621459.2014.951443","article-title":"A simple method for estimating interactions between a treatment and a large number of covariates","volume":"109","author":"Tian","year":"2014","journal-title":"J. Amer. Statist. Assoc."},{"key":"10.1016\/j.jbi.2023.104420_b39","article-title":"Some methods for heterogeneous treatment effect estimation in high-dimensions","volume":"37","author":"Powers","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.jbi.2023.104420_b40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/obs.2019.0005","article-title":"Causaltoolbox\u2014estimator stability for heterogeneous treatment effects","volume":"5","author":"K\u00fcnzel","year":"2019","journal-title":"Obs. Stud."},{"key":"10.1016\/j.jbi.2023.104420_b41","series-title":"Evaluating treatment prioritization rules via rank-weighted average treatment effects","author":"Yadlowsky","year":"2015"}],"container-title":["Journal of Biomedical Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1532046423001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1532046423001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T03:15:48Z","timestamp":1719803748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1532046423001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":41,"alternative-id":["S1532046423001417"],"URL":"https:\/\/doi.org\/10.1016\/j.jbi.2023.104420","relation":{},"ISSN":["1532-0464"],"issn-type":[{"value":"1532-0464","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of Biomedical Informatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbi.2023.104420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104420"}}